Oral transmucosal fentanyl citrate - OTFC (ACTIQ™) #103

Journal of Palliative Medicine

Volumn 11, Issue 4, 2008, Pages 633-634

  Gordon, Debra ^a   Schroeder, Mark ^b  

^a University of Wisconsin Health   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL CITRATE; FENTORA; HYDROMORPHONE; MORPHINE;

DIZZINESS; DRUG COST; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LOZENGE; NAUSEA; REPEATED DRUG DOSE; SHORT SURVEY; SINGLE DRUG DOSE; SOMNOLENCE;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; FENTANYL; HUMANS; NEOPLASMS; PAIN;

EID: 43049148361     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2008.9922     Document Type: Short Survey

References (3)

1. Fine PG, Streisand JB: A review of oral transmucosal fentanyl citrate: potent, rapid and noninvasive opioid analgesia. J Palliat Med 1998;1:55-63.
2. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 1999;79:303-312.
3. Physicians Desk Reference, 2003. Montvale, NJ: Thomson Healthcare, 2003.